0.3106
전일 마감가:
$0.187
열려 있는:
$0.3961
하루 거래량:
653.92M
Relative Volume:
52.55
시가총액:
$11.45M
수익:
-
순이익/손실:
$-12.89M
주가수익비율:
-0.1228
EPS:
-2.53
순현금흐름:
$-11.95M
1주 성능:
+52.30%
1개월 성능:
+3.14%
6개월 성능:
-71.44%
1년 성능:
-81.20%
Plus Therapeutics Inc Stock (PSTV) Company Profile
명칭
Plus Therapeutics Inc
전화
737.255.7194
주소
4200 MARATHON BLVD., AUSTIN, TX
PSTV을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
PSTV
Plus Therapeutics Inc
|
0.3101 | 11.45M | 0 | -12.89M | -11.95M | -2.53 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
444.36 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
518.46 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
322.87 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
562.49 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
267.30 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-03-17 | 개시 | D. Boral Capital | Buy |
2021-01-25 | 개시 | Ladenburg Thalmann | Buy |
2020-10-16 | 개시 | Maxim Group | Buy |
Plus Therapeutics Inc 주식(PSTV)의 최신 뉴스
Dow Surges 150 Points; Korn Ferry Earnings Top Views - Benzinga
Plus Therapeutics (PSTV) Sees Stock Dip Amid New Share Sale Fili - GuruFocus
Plus Therapeutics drops 5%, files prospectus for 17M share secondary offering (PSTV:NASDAQ) - Seeking Alpha
Plus Therapeutics (PSTV) Announces Sale of 17 Million Shares | P - GuruFocus
Plus Therapeutics Modifies Security Holders’ Rights - TipRanks
Leptomeningeal Metastases Pipeline 2025: MOA, ROA, - openPR.com
Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials - AlphaStreet
Plus Therapeutics Appeals Nasdaq Delisting Decision - TipRanks
Plus Therapeutics (NASDAQ:PSTV) Given New $20.50 Price Target at Ascendiant Capital Markets - Defense World
Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds - mx.advfn.com
Ascendiant Capital raises Plus Therapeutics stock price target By Investing.com - Investing.com South Africa
Ascendiant Capital raises Plus Therapeutics stock price target - Investing.com
PSTV: Ascendiant Capital Maintains Buy Rating and Raises Price T - GuruFocus
PSTV: Ascendiant Capital Maintains Buy Rating and Raises Price Target | PSTV Stock News - GuruFocus
Plus Therapeutics (NASDAQ:PSTV) Shares Down 6.9% – Here’s What Happened - Defense World
Plus Therapeutics Reports Q1 2025 Financial Results - TipRanks
Plus Therapeutics (PSTV) Reports Significant Q1 Earnings Miss - GuruFocus
Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates - MSN
Plus: Q1 Earnings Snapshot - New Haven Register
Plus Therapeutics reports Q1 EPS ($1.19) vs. (75c) last year - TipRanks
Plus Therapeutics (PSTV) Reports Financial Gains from Grant Reve - GuruFocus
Earnings Flash (PSTV) Plus Therapeutics Reports Q1 Loss $-1.19 Per Share, vs. FactSet Est of $-0.25 - marketscreener.com
Plus Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights | PSTV Stock News - GuruFocus
Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights - The Manila Times
PLUS THERAPEUTICS, INC. SEC 10-Q Report - TradingView
Plus Therapeutics, Inc. Reports Q1 2025 Financial Results and Updates on REYOBIQ™ Trials and CNSide® Assay Platform Progress - Nasdaq
Plus Therapeutics Clinical Trial Success: Cancer Drug REYOBIQ Extends Patient Survival to 17 Months - Stock Titan
Should Plus Therapeutics Inc (NASDAQ: PSTV) Investors Be Concerned? - Stocksregister
DeFi Technologies Provides Monthly Corporate Update: Valour Reports C$1.18 Billion (US$819 Million) AUM, and Record Monthly Net Inflows of C$56 Million (US$38.8 Million) in December 2024 - The Globe and Mail
3 No-Brainer Cloud Computing Stocks to Buy Right Now - The Globe and Mail
Plus Therapeutics recives Nasdaq delinquency notice - MSN
Plus Therapeutics, Inc. Receives Notification of Deficiency from - GuruFocus
Plus Therapeutics (PSTV) Faces Nasdaq Compliance Challenge - GuruFocus
Plus Therapeutics Faces Nasdaq Compliance Notice - TipRanks
Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q | PSTV Stock News - GuruFocus
Plus Therapeutics, Inc. Receives Notification of Deficiency - GlobeNewswire
Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q - TradingView
SBAC Stock Rises 12% Year to Date: Will the Trend Continue? - The Globe and Mail
Plus Therapeutics soars on FDA Orphan Drug Designation for lung cancer treatment - MSN
Plus Therapeutics Receives Nasdaq Delisting Notice - TipRanks
Corpay Stock Jumps 25% in a Year: Here's What You Should Know - The Globe and Mail
Tesla Stock Powers Up for Fourth Straight Week of Gains - The Globe and Mail
Plus Therapeutics Delays Quarterly Report Filing - TipRanks
Plus Therapeutics (PSTV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - MSN
Plus Therapeutics reports progress in CNS cancer therapy By Investing.com - Investing.com Nigeria
Plus Therapeutics Inc (PSTV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Plus Therapeutics Inc 주식 (PSTV) 내부자 거래
내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
---|---|---|---|---|---|---|---|
Hawkins Richard J | Director |
Sep 13 '24 |
Buy |
1.50 |
4,000 |
5,996 |
15,188 |
Hawkins Richard J | Director |
Sep 12 '24 |
Buy |
1.35 |
6,285 |
8,512 |
11,188 |
Petersen Greg | Director |
Sep 11 '24 |
Buy |
1.35 |
12,500 |
16,875 |
48,921 |
Clowes Howard | Director |
Sep 11 '24 |
Buy |
1.34 |
5,000 |
6,681 |
26,497 |
HEDRICK MARC H | Chief Executive Officer |
Sep 10 '24 |
Buy |
1.23 |
8,000 |
9,839 |
20,425 |
Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Sep 10 '24 |
Buy |
1.27 |
4,098 |
5,204 |
9,815 |
자본화:
|
볼륨(24시간):